This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This lets you focus on what matters most: driving meaningful results in drugresearch and development. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data.
Your Definitive Source of Truth The Data Dictionary is tailored to transform your data experience, offering the official DrugBank perspective on every piece of information in our database. This means you have precise, detailed information for each data point, eliminating guesswork and boosting your confidence in using our data effectively.
He will also draw from exclusive information found in DCI's new 2024 Economic Report on U.S. The potential effect of the IRA on manufacturers’ new drugresearch and development strategies is beyond the scope of this webinar. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.
Research is emerging at a never before seen rate, and it is causing challenges for researchers and scientists to not only stay on top of the latest publications, but to validate conflicting information. They also have a reputation of containing hidden inaccuracies and out-of-date information.
Planning for an early AME study with Worldwide will not only satisfy FDA requirements, but its data can also contribute valuable information to the start of your clinical trial and help anticipate what your compound will need for approval, thereby saving time and reducing costs.
In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drugresearch. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2
The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drugresearch today. One approach is to look beyond the traditional drug molecule.
“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. For more information on the critical gap in pharma omnichannel engagement, read the eBook. We’re excited to see ACTO driving this transformation in the industry.”
This requirement was included in the section of the bill that expanded FDA authority for BIMO inspections, including allowing it access to electronic information and expanding the types of facilities subject to BIMO inspections.
The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drugresearch and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs.
Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients, and it has also been granted authorizations in several additional countries. For more information about the use of bamlanivimab in the U.S., The webcast information is available here.
For more information, please visit: www.innoventbio.com. Liu mentioned that he will utilize his knowledge, past experience and worldwide network to lead Innovent into the new decade with even better achievement and grow the company into a truly global first class biopharmaceutical company. View original content to download multimedia: [link].
It introduced concepts like informed consent and risk/benefit analysis for clinical studies. I think there was still worthwhile information that came out of COVID challenge models, and there's plenty of future value, especially if we work on a broad-spectrum coronavirus family vaccine of some sort. That's what Josh was getting at.
ACTIV was founded last April to accelerate drugresearch that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. And ACTIV has indeed moved at unprecedented speed since its launch.
Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drugresearch. For further information, visit www.riverbiomedics.com
In a study of more than 12,000 small molecule drugs , researchers found 40.4% This means that entire classes of critical drugs (like ACE inhibitors and beta blockers) containing secondary or tertiary amine moieties in their API molecular structures are technically nitrosamine precursors. Read below for more information on this.
For example, on July 25, the Hungarian presidency hosted an informal meeting of health ministers to discuss health issues, such as mitigating the effect of cardiovascular diseases and implementing the European Health Data Space (EHDS).
These API-derived nitrosamines are referred to as Nitrosamine Drug Substance Related Impurities (NDSRIs) and represent an unprecedented development with manufacturing, quality, and product safety implications. In a study of more than 12,000 small molecule drugs , researchers found 40.4%
New era in drugresearch: data access and NGS The 1990s and 2000s marked a turning point in the drug development landscape, facilitated by a combination of cultural and technological factors that enabled regulatory changes, technological innovations and methodological advances.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content